Sociedad Americana de Hirudoterapia

Antithrombotic prophylaxis following total knee arthroplasty: a level I Bayesian network meta-analysis.

Review published in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie (2024)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Systematic reviewEnsayos clínicosDesarrollo de fármacosMigliorini et al. · European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2024

Abstract

INTRODUCTION: Venous thromboembolism (VTE) is a major concern following total knee arthroplasty (TKA). The optimal pharmacological prophylaxis remains, however, controversial. The present investigation compared several non-vitamin K antagonist oral anticoagulants commonly employed as VTE prophylaxis following TKA. A Bayesian network meta-analysis was conducted to compare apixaban, aspirin, dabigatran, edoxaban, enoxaparin, fondaparinux, and rivaroxaban. The outcomes of interest were to compare the rate of deep venous thrombosis (DVT), pulmonary embolism (PE), and major and minor haemorrhages. METHODS: This study was conducted according to the PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-Analyses of Health Care Interventions. In March 2024, PubMed, Web of Science, and Google Scholar were accessed with no time constraints. All randomised controlled trials (RCTs) comparing two or more drugs for the prevention of VTE following TKA were considered for inclusion. RESULTS: Data from 29,678 patients were collected. Of them, 67% (19,884 of 29,678 patients) were women. The mean age of the patients was 66.8 ± 2.8 years, and the mean BMI was 29.2 ± 1.5 kg/m2. There was comparability in age, sex, and BMI at baseline. Apixaban 5 mg, dabigatran 220 mg, and rivaroxaban 10 mg were the most effective in reducing the rate of DVT. Apixaban 5 mg, enoxaparin 60 mg, and rivaroxaban 40 mg were the most effective in reducing the rate of PE. Apixaban 5 mg, rivaroxaban 10 mg, and apixaban 10 mg were associated with the lowest rate of major haemorrhages. Apixaban 5 mg and 20 mg, and dabigatran 220 mg were associated with the lowest rate of minor haemorrhages. CONCLUSION: Administration of apixaban 5 mg demonstrated the best balance between VTE prevention and haemorrhage control following TKA. LEVEL OF EVIDENCE: Level I, network meta-analysis of RCTs.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleSystematic ReviewNetwork Meta-Analysis
Indexed MeSH termsHumansArthroplasty, Replacement, KneeBayes TheoremVenous ThromboembolismRivaroxabanPyridonesAnticoagulantsPostoperative ComplicationsDabigatranPyrazolesAspirinFibrinolytic Agents

Resumen

Venous thromboembolism (VTE) is a major concern following total knee arthroplasty (TKA). The optimal pharmacological prophylaxis remains, however, controversial.

Por qué esto importa para la hirudoterapia

This Bayesian network meta-analysis compared apixaban, aspirin, dabigatran, edoxaban, enoxaparin, fondaparinux, and rivaroxaban for venous thromboembolism prophylaxis following total knee arthroplasty across 29,678 patients from randomized controlled trials, concluding that apixaban 5 mg offered the best balance between VTE prevention and hemorrhage control. The study has minimal direct relevance to hirudotherapy or the leech secretome, as none of the compared agents are derived from or structurally related to hirudin or leech-produced compounds. Caveat: This is a comparative effectiveness analysis of conventional oral and injectable anticoagulants with no involvement of leeches, hirudin, bivalirudin, or any leech-derived substance; any relevance to ASH's domain is limited to the broader anticoagulation pharmacotherapy landscape.

Citación

Antithrombotic prophylaxis following total knee arthroplasty: a level I Bayesian network meta-analysis.

Migliorini et al. · European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2024

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.